---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116777"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:56:50.049880+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast

## Summary
- Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.
- Oncology tests 137,100 (+54.4%); total tests processed 775,800 (+23.9%).
- Net loss narrowed to $31.6M ($0.26/sh) from $109M ($0.95/sh); positive cash flow $34.5M.
- 2024 guidance raised: revenue $1.61-1.64B, gross margin 58-61%, net cash inflow $50-75M.
- Cash $922.3M; all convertible notes redeemed/converted on Oct 11, 2024.

## SEC filing metadata
- accession: 0001104659-24-116777
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465924116777/0001104659-24-116777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465924116777/tm2427439d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116777
- JSON: https://secwatch.observer/filing/0001104659-24-116777.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.